More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/TOFA [54857-86-2]
Chemical Structure
Chemical Structure
Chemical Structure

TOFA [54857-86-2]

Research Use Only
AG-CR1-2905
AdipoGen Life Sciences
CAS Number54857-86-2
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight324.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    TOFA [54857-86-2]
  • Delivery Days Customer
    10
  • CAS Number
    54857-86-2
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C19H32O4
  • Molecular Weight
    324.5
  • Scientific Description
    Chemical. CAS: 54857-86-2. Formula: C19H32O4. MW: 324.5. . Fatty acid synthase (FASN) inhibitor. Cell-permeable, potent, reversible and competitive inhibitor of acetyl-CoA carboxylase (ACC) consequently bocking the synthesis of malonyl-CoA. Useful agent for immunometabolism research. Anticancer agent. Induces apoptosis in a variety of tumor cell lines. Relatively non-cytotoxic to various cancer cell lines. TOFA-induced reduction in malonyl-CoA is reported to off-set the effect of C75 on food intake in fasted mice and on apoptosis in tumor cells. Hypolipidemic agent. Stimulates citrate accumulation in the cell, which leads to a suppression of glycolysis by citrate-induced inhibition of phosphofructokinase. - Fatty acid synthase (FASN) inhibitor. Cell permeable, potent, reversible and competitive inhibitor of acetyl-CoA carboxylase (ACC) consequently blocking the synthesis of malonyl-CoA. Useful agent for immunometabolism research. Anticancer agent. Induces apoptosis in a variety of tumor cell lines. Relatively non-cytotoxic to various cancer cell lines. TOFA-induced reduction in malonyl-CoA is reported to off-set the effect of C75 (AG-CR1-2904) on food intake in fasted mice and on apoptosis in tumor cells. Hypolipidemic agent. Stimulates citrate accumulation in the cell, which leads to a suppression of glycolysis by citrate-induced inhibition of phosphofructokinase.
  • SMILES
    CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids: R.A. Parker, et al.; J. Med. Chem. 20, 781 (1977)
  • Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid: D.L. Halvorson & S.A. McCune; Lipids 19, 851 (1984)
  • Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines: E.S. Pizer, et al.; Cancer Res. 58, 4611 (1998)
  • Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors: T.M. Loftus, et al.; Science 288, 2379 (2000)
  • Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity: J.N. Thupari, et al.; BBRC 285, 217 (2001)
  • Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells: W. Zhou, et al.; Cancer Res. 63, 7330 (2003)
  • C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism: L.E. Landree, et al.; J. Biol. Chem. 279, 3817 (2004)
  • TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status: N.V. Guseva, et al.; Cancer Biol. Ther. 12, 80 (2011)
  • A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)